A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis (CRAFT)
Cross-over, Randomized, Open-label, Single-centre, Phase II Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
The goal of this open-label clinical trial is to evaluate the efficacy of AzaFol-PET/CT in the diagnosis of GCA (giant cell arteritis), to compare AzaFol- with 2-[18F]FDG-PET/CT, and to assess the safety and tolerability of AzaFol in subjects with suspicion of GCA.
Participants will undergo AzaFol-PET/CT imaging at a single timepoint.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Britta Maurer
- Phone Number: +41 31 63 2 7229
- Email: RI-Studien@insel.ch
Study Locations
-
-
-
Bern, Switzerland, 3010
- Recruiting
- Department of Rheumatology and Immunology, University Hospital Bern, Inselspital
-
Contact:
- Britta Maurer, Prof. Dr. med.
- Phone Number: +41 31 63 2 72 29
- Email: RI-Studien@insel.ch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individuals ≥ 50 years with clinical suspicion of GCA
- Women of childbearing potential must not have a positive serum pregnancy test at the Screening Visit
- Subjects must be able to understand and adhere to all protocol requirements and must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures.
- Are willing and able to comply with procedures required in this protocol.
Exclusion Criteria:
- Folate deficiency
- Female subjects who are pregnant, breastfeeding, or considering becoming pregnant during the study or within 30 days after the last dose of study drug
- Concomitant treatment with medications that lead to a significant impairment of folic acid levels (methotrexate, pemetrexed, raltitrexed)
- Concomitant glucose-containing infusion or parental nutrition within 6 hours prior to 2-[18F]FDG tracer application
- Glucose level > 10 mmol/l at the timepoint of 2-[18F]FDG PET/CT
- Unable to remain in the PET/CT for the duration of the examination
- Unable to lie still for the duration of the examination (45 min)
- Unable not to eat or drink (except water) for 6 hours prior to 2-[18F]FDG tracer application
- Prior PET-imaging within 60 days before baseline
- Intake of vitamin supplements containing > 1mg/day folic acid within 48 h prior to the PET/CT with AzaFol
- Known hypersensitivity or allergy to folic acid
- Enrolment of the investigator, his/her family members, employees and other dependent persons
- Participation in another study with investigational drug within the 7 days preceding and during the present study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AzaFol first, FDG second
AzaFol PET/CT imaging followed by FDG PET/CT imaging (standard of care)
|
AzaFol-PET/CT imaging
FDG-PET/CT imaging
|
|
Active Comparator: FDG first, AzaFol second
FDG PET/CT imaging (standard of care) imaging followed by AzaFol PET/CT
|
AzaFol-PET/CT imaging
FDG-PET/CT imaging
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Specificity of the GCA-diagnosis at the patient level
Time Frame: Baseline
|
Specificity of the GCA-diagnosis at the patient level using visual analysis as a diagnostic method with the clinical expert diagnosis as the reference standard
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lesion detection rate (visual analysis)
Time Frame: Baseline
|
Lesion detection rate in PET/CT in patients with suspicion of GCA, in patients with GCA (clinical expert diagnosis), and in patients without GCA (clinical expert diagnosis) by visual analysis at the level of the vessel.
|
Baseline
|
|
Lesion detection rate (semiquantitative analysis)
Time Frame: Baseline
|
Lesion detection rate in PET/CT in patients with suspicion of GCA, in patients with GCA (clinical expert diagnosis), and in patients without GCA (clinical expert diagnosis) by semiquantitative analysis at the level of the vessel.
|
Baseline
|
|
Sensitivity of the GCA-diagnosis at the patient level
Time Frame: Baseline
|
Sensitivity of the GCA-diagnosis at the patient level using visual evaluation as a diagnostic method with the clinical expert diagnosis as the reference standard.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Britta Maurer, Department of Rheumatology and Immunology, Inselspital, University of Bern, Bern, Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Autoimmune Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Skin Diseases
- Skin Diseases, Vascular
- Vasculitis
- Vasculitis, Central Nervous System
- Arteritis
- Skin and Connective Tissue Diseases
- Giant Cell Arteritis
Other Study ID Numbers
Other Study ID Numbers
- CRAFT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.